Monitor the IASP poster session for any incremental efficacy or safety data on TONMYA that could influence physician adoption or payer coverage. The next material catalyst is likely the full Q3 2026 earnings release with finalized revenue and cash burn details.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced a poster presentation on TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia at the IASP 2026 World Congress on Pain in Bangkok, October 26-30, 2026. This is a routine scientific dissemination event with no new clinical data or regulatory catalyst disclosed. The filing is neutral as it does not contain material financial or operational updates beyond the previously reported preliminary Q3 2026 TONMYA net revenue of $14M-$15M.
Key Facts
- Poster on TONMYA effects on fibromyalgia symptoms and physical function to be presented at IASP 2026 World Congress on Pain, October 26-30, 2026 in Bangkok.
- TONMYA was FDA-approved on August 15, 2025 and commercially launched November 17, 2025.
- No new clinical data, financial results, or regulatory updates in this press release.
- Cross-filing 8-K (Oct 15, 2026) disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M and estimated cash of $162.8M.
Financial Impact
No new financial data in this release; prior preliminary Q3 2026 TONMYA net revenue $14M-$15M per cross-filing.
Risk Factors
- TONMYA revenue growth may decelerate from Q2's $11M to Q3's $14M-$15M if competition or payer pushback intensifies.
- Cash burn of ~$84.6M in H1 2026 raises financing risk; cash runway may require additional capital within 12 months.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383285 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.17 (−9.77%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.17 (−19.47%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.17 (+35.94%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.17 (−51.18%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.17 (−60.71%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.17 (−58.94%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.17 (−58.94%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.17 (−51.55%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.17 (−50.14%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.17 (−55.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers